Several brokerages have updated their recommendations and price targets on shares of NeoGenomics (NASDAQ: NEO) in the last few weeks:

  • 10/29/2017 – NeoGenomics had its “hold” rating reaffirmed by analysts at BTIG Research. They wrote, “Sidelines Until Optics Improve; Neutral With NEO having previewed Q3 results two weeks ago, there were seemingly less fireworks accompanying today’s print. Overall, we remain optimistic on the volume front as Q3 results beat our expectations. We also think there continues to be potential for upside on the BioPharma front given encouraging backlog numbers. In our view, the magnitude of the share pullback naturally warrants a closer look but given the introduction of some risk around payor reimbursement in NGS testing (discussed in today’s call) and still elevated bad debt levels in Q4, we do not feel there is a sense of urgency to own the name until there is more clarity around FY18 profitability and/or optics improve in the 1H18. Maintain our Neutral rating.   First, the good news… Even with the Hurricane, same-store volume growth was ~17%, a tad better than our expectations for mid-teens growth.””
  • 10/26/2017 – NeoGenomics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. “
  • 10/26/2017 – NeoGenomics had its “buy” rating reaffirmed by analysts at Janney Montgomery Scott.
  • 10/20/2017 – NeoGenomics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. “
  • 10/18/2017 – NeoGenomics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 10/13/2017 – NeoGenomics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. “
  • 10/5/2017 – NeoGenomics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company’s testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. “
  • 9/23/2017 – NeoGenomics was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 9/13/2017 – NeoGenomics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 9/11/2017 – NeoGenomics was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating.

NeoGenomics (NASDAQ:NEO) last released its earnings results on Wednesday, October 25th. The medical research company reported $0.01 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.01. NeoGenomics had a negative net margin of 4.78% and a positive return on equity of 3.98%. The firm had revenue of $63.05 million during the quarter, compared to analyst estimates of $63.11 million. During the same period last year, the business earned $0.04 earnings per share. The business’s revenue was up 3.8% on a year-over-year basis.

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Receive News & Ratings for NeoGenomics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc and related companies with MarketBeat.com's FREE daily email newsletter.